Zacks Research Issues Optimistic Forecast for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.98 for the quarter, up from their prior forecast of $0.97. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $4.50 EPS, Q3 2026 earnings at $1.38 EPS and Q4 2026 earnings at $1.63 EPS.

Several other research firms have also commented on HALO. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Piper Sandler raised their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a report on Monday, December 30th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $53.76 on Thursday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company’s 50-day moving average price is $50.16 and its 200 day moving average price is $54.00. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC boosted its position in Halozyme Therapeutics by 34.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 20,382 shares of the biopharmaceutical company’s stock worth $1,067,000 after purchasing an additional 5,210 shares during the period. Private Advisor Group LLC grew its position in Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 412 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $195,000. Texas Permanent School Fund Corp lifted its position in shares of Halozyme Therapeutics by 6.0% during the second quarter. Texas Permanent School Fund Corp now owns 121,635 shares of the biopharmaceutical company’s stock worth $6,369,000 after purchasing an additional 6,890 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Halozyme Therapeutics by 9.7% in the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after purchasing an additional 72,544 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.